ALK and non-small cell lung carcinoma: Molecular tests, such as analysis of Epidermal Growth Factor Receptor (EGFR) mutations (exons 18, 19, 20, 21) and Anaplastic Lymphoma Kinase (ALK) fusion gene, are prescribed in non-squamous NSCLC to determine the responsiveness to Tyrosine Kinase Inhibitors (TKIs) or ALK inhibitors, respectively [2].